Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global healthcare budgets.

LEHI, Utah--(BUSINESS WIRE)--Xevant, a leader in pharmacy benefits automation, today announces the launch of its all-new Biosimilar Dashboard, a real-time analytics tool designed to streamline ...

CVS is far from the only one with interest in making cheaper versions of popular prescription drugs. Biosimilar versions of Humira, specifically, have been top of mind for drug companies and ...

A systematic literature review published in JAMA Dermatology provides proof that biosimilar drugs are safe and effective in treating psoriasis.An analysis of clinical studies that compared ...

Drugmaker Amgen on Tuesday launched a biosimilar to the widely-prescribed Humira, giving consumers an alternative to the world's top-selling rheumatoid arthritis drug.. The new drug, Amjevita ...

A provision in 2022's Inflation Reduction Act injected massive uncertainty into the biosimilar market, and could keep dozens of cost-saving biosimilars from ever making it to patients.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what ...

Despite eight cheaper biosimilar competitors, blockbuster anti-inflammatory Humira still dominates its market. What’s going on?

The biosimilar price is about 85% lower than that of branded Humira, according to the announcement. More than 100,000 Accredo patients use either Humira or one of its biosimilars, the company said.

Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences's biosimilar version of ...

Evernorth Health Services, a subsidiary of Cigna, plans to have a Stelara biosimilar available for $0 out-of-pocket cost for eligible patients of its specialty pharmacy, Accredo, beginning in early ...

Enter biosimilar medications. These medications are near copies of biologic medications with (typically) a much lower price tag. It’s easy to wonder if less expensive means they’re less effective.